|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
|
|---|---|---|
| Operating expenses: | ||
| General and administrative | ||
| Research and development | ||
| In-process research and development (IPR&D) -Teverelix | ||
| Total operating expenses | ||
| Loss from operations | ||
| Other income (expense) | ||
| Finance (income) expense, net | ||
| Interest income (expense) | ||
| Loss on SEPA settlements | ||
| Change in fair value of debentures | ||
| Loss on extinguishment of debentures | ||
| Total other income (expense) | ||
| Net loss for the year | ||
| Deemed dividend on warrant inducement | ||
| Net loss for the year attributable to common shareholders | ||
| Foreign currency translation adjustment | ||
| Comprehensive loss for the year attributable to common shareholders | ||
| Supplemental Income Statement Elements | ||
| Net loss attributable to | ||
| Common shareholders of the Company | ||
| Non-controlling interests | ||
| Comprehensive loss attributable to | ||
| Common shareholders of the Company | ||
| Non-controlling interests | ||
| Net loss per share attributable to common shareholders - basic | ||
| Net loss per share attributable to common shareholders - diluted | ||
| Weighted average number of common shares outstanding - basic | ||
| Weighted average number of common shares outstanding - diluted |
Loading...
